Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo pharma b.v. - drospirenone 3 mg (pink tablet); ethinylestradiol 0,02 mg (pink tablet); placebo (white tablet) - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol 0.02 mg; placebo - drospirenone and ethinylestradiol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - drospirenone 3 mg (pink tablet); ethinylestradiol 0,02 mg (pink tablet); placebo (white tablet) - film-coated tablet - 0,02 mg - 3 mg - ethinylestradiol 0.02 mg; drospirenone 3 mg; placebo - drospirenone and ethinylestradiol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

effik benelux sa-nv - drospirenone 3 mg (pink tablet); ethinylestradiol 0,02 mg (pink tablet); placebo (white tablet) - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol 0.02 mg; placebo - drospirenone and ethinylestradiol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - drospirenone 3 mg (pink tablet); ethinylestradiol 0,02 mg (pink tablet); placebo (white tablet) - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol 0.02 mg; placebo - drospirenone and ethinylestradiol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

theramex ireland ltd. - drospirenone 3 mg (pink tablet); ethinylestradiol 0,02 mg (pink tablet); placebo (white tablet) - film-coated tablet - 0,02 mg - 3 mg - ethinylestradiol 0.02 mg; drospirenone 3 mg; placebo - drospirenone and ethinylestradiol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol betadex clathrate - eq. ethinylestradiol 0,02 mg (light pink tablet); drospirenone 3 mg (light pink tablet); placebo (white tablet) - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol betadex clathrate; placebo - drospirenone and ethinylestradiol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - drospirenone 3 mg (light pink tablet); ethinylestradiol 0,02 mg (light pink tablet); placebo (white tablet) - film-coated tablet - 0.02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol 0.02 mg; placebo - drospirenone and ethinylestradiol

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - drospirenone 3mg (micro 15); ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg) - tablet - 3mg/0.02mg - active: drospirenone 3mg (micro 15) ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg) excipient: lactose monohydrate magnesium stearate maize starch opadry pink 02a34744 hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified talc titanium dioxide hypromellose lactose monohydrate magnesium stearate maize starch povidone purified talc titanium dioxide - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome).

Malta - English - Medicines Authority

mithra pharmaceuticals s.a rue saint-georges 5, 4000, liege, belgium - ethinylestradiol, drospirenone - film-coated tablet - ethinylestradiol 0.2 mg drospirenone 3 mg - sex hormones and modulators of the genital system

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.